Yesterday, Knight Therapeutics reported its Q1, 2016 results. The company earned $477,000 on revenue of $1.06-million.
“We are off to a ‘GUD’ start in 2016 having signed long-term partnerships with Braeburn, EMPA, Intega and Medimetriks,” said CEO Jonathan Ross Goodman. “Rest assured that the Knight team is working diligently toward deploying capital in low-risk, fair-return opportunities.”
Walewicz notes that management has said it is working on some eighty opportunities and the potential for upside from M&A is solid.
“Over the next 18 months commercial activities should ramp up as GUD prepares for key Rx product launches, including Iluvien, Probuphine and ATryn (all pending Health Canada approval), as well as AzaSite (approved),” says the analyst. “We continue to believe that the current market turmoil will present opportunities to well capitalized companies, including Knight.”
In a research update to clients today, Walewicz maintained his “Hold” rating and one-year price target of $8.50 on Knight Therapeutics, implying a return of 2.4 per cent at the time of publication.
Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]
Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]
Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]
A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]
Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]
The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]